Please login to the form below
Cytokinetics
This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
Following the publication of the results, shares in Amgen dropped down by 4.6%, with shares in California-based Cytokinetics falling by 43%. ... Omecamtiv mecarbil, originally developed by Cytokinetics, is designed to increase the duration of cardiac
Latest news
-
Trial of Amgen, Servier’s heart failure drug clears interim check
Originally developed by Cytokinetics, omecamtiv mecarbil is the first in a new class of drugs – dubbed cardiac myosin activators – that are designed to increase the duration of cardiac muscle contractility and
-
Amgen, Servier heart failure drug clears trial hurdle
Originally developed by Cytokinetics, omecamtiv is the first in a new class of drugs called cardiac myosin activators, that are designed to increase the duration of cardiac muscle contractility and improve ... Amgen recently started phase 1 trials of
-
Amgen, Servier start second phase 3 trial of heart failure hope
Originally developed by Cytokinetics, omecamtiv is the first in a new class of drugs designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance in heart failure. ... Amgen, Servier and Cytokinetics are
-
Roche reshuffles its executive committee, again
Prior to joining Genetech Sabry was chief executive officer for start-up biotech and was founder and chief executive of biopharma Cytokinetics.
-
Amgen agrees to take Cytokinetics' heart failure drug into phase III
originator, Cytokinetics, which has been waiting for the big biotech to make a decision for several weeks. ... Cytokinetics said recently that meetings have been held with both the FDA and EMA to discuss the design of the outcomes study, which is due to
More from news
Approximately 5 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
-
Deal Watch July 2016
Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and
-
Astellas: Ten years young
option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.
-
Heart failure therapy embarks on a new era
In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.
-
Deal Watch table for December 2014
Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director - Med Comms Agency
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Sinovac’s COVID-19 vaccine appears safe in older adults
- STEM Healthcare founder Rob Wood secures a 25% stake in performance-io
- Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- AZ sells stake in Moderna for around $1.2bn
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- Syneos Health Communications announces senior hires to Europe-based team
- First shipments of AZ/Oxford COVID-19 vaccine sent through COVAX
- Merck & Co to help produce J&J’s COVID-19 vaccine in the US
- AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset
- Andi Goes – the children’s book that helps detect early signs of dyslexia
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
- A cultural shift in clinical research
- Research organisations across the board are experimenting with new technologies...
Quick links
Infographics
